When: Q3 EPS in line or better than Q2's $1.23 with forward $9.30+ held or revised upward

Then: Upgrade to Overweight

When: Two consecutive quarters of bioprocessing stabilization

Then: Upgrade to Overweight

When: Credible $9.84B deal synergy disclosure with operating margin recovery above 20%

Then: Upgrade to Overweight

When: Slightly soft Q3 EPS with strong 2027 commentary + dovish macro surprise

Then: Trim back to neutral weight

HOLD with 25-30% trim before Q3; maintain $197.50 invalidation level; re-add only after confirmed results

• 200 SMA has been flat to declining: $203.40 in June, $201.99 now—previously breached in July, dropped to $160s before recovery, currently replaying that pattern
• 6 bearish technical signals confirmed, 460 basis point sequential margin compression, SG&A growing faster than revenue
• TTM EPS base of $5.61 depressed by $432M impairment in Q2 2025 and post-COVID testing normalization; forward $9.30 is recovery to normal earnings, not re-acceleration
• Forward P/E of 21.6x already pricing recovery; if Q3 misses, stock drops AND multiple compresses—'hit twice'
• M&A created $8B new debt, net debt jumped $13.8B to $22.2B; goodwill +$4.7B, intangibles +$4.2B; Net debt/EBITDA at 2.77x crosses 3.0x if EBITDA slips 10%
• Beta of 0.81 does not equal protection—5-year DHR return is negative 26.6% vs S&P 500 compounding
• Zero Reddit posts = zero retail bid, not 'coiled spring'; no marginal buyer below $200 if institutions de-risk
• Polymarket pricing 93% odds of zero Fed cuts in 2026 caps multiple expansion for high-multiple healthcare equipment

→ vs aggressive: 200 SMA as 'structural floor' is flawed—the line was breached in July, dropped to $160s; current setup is a replay of that failed pattern, not a fortress

→ vs aggressive: 'Leave money on the table' framing is backwards—a 25-30% trim is asymmetric protection against Q3 disappointment; aggressive plan keeps 100% downside for ~60% upside

→ vs aggressive: 66% EPS expansion treats forecast as fact; $5.61 TTM was depressed by $432M impairment, so $9.30 is normalized recovery not step-function re-acceleration

→ vs aggressive: M&A is not a 'free call option'—it cost $8B in new debt, pushed net debt to $22.2B, and goodwill/intangibles jumped $4.7B/$4.2B respectively; bad integration = 8-12% one-day write-down event

→ vs aggressive: Defensive compounder narrative ignores 5-year return of negative 26.6%; beta measures correlation, not protection, and macro provides no tailwind

→ vs aggressive: 'Coiled spring' sentiment requires buyers from somewhere—most likely same institutional accounts currently holding; they have to sell to each other

Maintain core position with 15-20% calibrated trim before Q3; consider protective put or collar hedge; keep $197.50 as invalidation level; flexible re-entry if forward trajectory intact

• Forward EPS $9.30 is recovery to normalized earnings power, not genuine organic acceleration; trailing $5.61 was depressed by $432M impairment
• 200 SMA is a tactical bounce level where institutional flows respect the price, not a guaranteed structural floor
• Recommend 15-20% trim (not 25-30%) to preserve upside participation while reducing binary risk
• Fundamentals intact: $4.3 billion trailing FCF, 4.5x dividend coverage ratio, exceptional M&A track record
• M&A concerns valid: $8 billion new debt issued, $4.7 billion goodwill jump creates integration risk; next two quarters determine premium justification
• Beta of 0.81 provides defensive characteristics over 6-12 month horizon but 5-year return of negative 26.6% undermines 'safety trade' framing long-term
• Zero Reddit posts signals absence of marginal demand, not a coiled spring; no retail bid to absorb institutional de-risking
• $197.50 is firm invalidation level where structural setup breaks requiring reassessment
• Re-entry framework should consider print quality plus forward commentary plus macro backdrop, not require binary 'clean print' proof
• Hedge structures preserve more upside than position reduction alone

→ vs aggressive: Forward EPS expansion framed as re-rating catalyst is incorrect; $9.30 is recovery to normalized earnings, not organic acceleration from $5.61 depressed base

→ vs aggressive: 200 SMA as 'structural floor' or 'fortress' is hindsight dressed as conviction; stock has been whipsawed through it repeatedly in this regime

→ vs aggressive: 'Leaving money on the table' framing ignores six bearish technical signals, sequential margin compression, macro headwinds, and binary catalyst risk; expected value doesn't favor full size

→ vs conservative: 25-30% trim is slightly too aggressive given intact fundamentals; should be one tool in the plan, not the centerpiece

→ vs conservative: 'Clean print' definition is too narrow; modest Q3 miss with strong 2027 commentary is a different scenario than guidance cut; rigid binary re-entry allows market to reclaim position before proof arrives